Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Limitations and Challenges in Mapping Ventricular Tachycardia: New Technologies and Future Directions.

Graham AJ, Orini M, Lambiase PD.

Arrhythm Electrophysiol Rev. 2017 Aug;6(3):118-124. doi: 10.15420/aer.2017.20.1.

2.

Dutch outcome in implantable cardioverter-defibrillator therapy (DO-IT): registry design and baseline characteristics of a prospective observational cohort study to predict appropriate indication for implantable cardioverter-defibrillator.

van Barreveld M, Dijkgraaf MGW, Hulleman M, Boersma LVA, Delnoy PPHM, Meine M, Tuinenburg AE, Theuns DAMJ, van der Voort PH, Kimman GP, Buskens E, Tijssen JPG, Bruinsma N, Verstraelen TE, Zwinderman AH, van Dessel PHFM, Wilde AAM; DO-IT investigators.

Neth Heart J. 2017 Aug 7. doi: 10.1007/s12471-017-1016-x. [Epub ahead of print]

3.

Antitachycardia pacing programming in implantable cardioverter defibrillator: A systematic review.

De Maria E, Giacopelli D, Borghi A, Modonesi L, Cappelli S.

World J Cardiol. 2017 May 26;9(5):429-436. doi: 10.4330/wjc.v9.i5.429. Review.

4.

Relationship between right and left ventricular function in candidates for implantable cardioverter defibrillator with low left ventricular ejection fraction.

Jimenez-Juan L, Karur GR, Connelly KA, Deva D, Yan RT, Wald RM, Singh S, Leung G, Oikonomou A, Dorian P, Angaran P, Yan AT.

J Arrhythm. 2017 Apr;33(2):134-138. doi: 10.1016/j.joa.2016.07.005. Epub 2016 Aug 31.

5.

Long-Term Prognosis of Patients with an Implantable Cardioverter-Defibrillator in Korea.

Uhm JS, Kim TH, Kim IC, Park YA, Shin DG, Lim YM, Yu HT, Yang PS, Pak HN, Kang SM, Lee MH, Joung B.

Yonsei Med J. 2017 May;58(3):514-520. doi: 10.3349/ymj.2017.58.3.514.

6.

Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials.

Shun-Shin MJ, Zheng SL, Cole GD, Howard JP, Whinnett ZI, Francis DP.

Eur Heart J. 2017 Jun 7;38(22):1738-1746. doi: 10.1093/eurheartj/ehx028.

7.

Implantable Cardioverter-Defibrillators for Secondary Prevention of Sudden Cardiac Death: A Review.

Borne RT, Katz D, Betz J, Peterson PN, Masoudi FA.

J Am Heart Assoc. 2017 Mar 3;6(3). pii: e005515. doi: 10.1161/JAHA.117.005515. Review. No abstract available.

8.

Effect of Sleep-Disordered Breathing on Appropriate Implantable Cardioverter-Defibrillator Therapy in Patients With Heart Failure: A Systematic Review and Meta-Analysis.

Kwon Y, Koene RJ, Kwon O, Kealhofer JV, Adabag S, Duval S.

Circ Arrhythm Electrophysiol. 2017 Feb;10(2):e004609. doi: 10.1161/CIRCEP.116.004609. Review.

9.

Echocardiographic evaluation of systolic heart failure.

Lo Q, Thomas L.

Australas J Ultrasound Med. 2009 Nov;12(4):21-29. doi: 10.1002/j.2205-0140.2009.tb00067.x. Epub 2015 Dec 31.

10.

Effectiveness of Implantable Cardioverter-Defibrillator Therapy for Heart Failure Patients according to Ischemic or Non-Ischemic Etiology in Korea.

Park KH, Lee CH, Jung BC, Cho Y, Bae MH, Kim YN, Park HS, Han S, Lee YS, Hyun DW, Kim J, Kim DK, Cha TJ, Shin DG.

Korean Circ J. 2017 Jan;47(1):72-81. doi: 10.4070/kcj.2016.0242. Epub 2016 Dec 27.

11.

ICD Implantation Practice Within Europe: How To Explain The Differences Beyond Economy?

Stella BM, Alessandro Z.

J Atr Fibrillation. 2015 Oct 31;8(3):1262. doi: 10.4022/jafib.1262. eCollection 2015 Oct-Nov. Review.

12.

Co-Morbidities and Cardiac Resynchronization Therapy: When Should They Modify Patient Selection?

Ruwald MH.

J Atr Fibrillation. 2015 Jun 30;8(1):1238. doi: 10.4022/jafib.1238. eCollection 2015 Jun-Jul. Review.

13.

A Questionable Indication For ICD Extraction After Successful VT Ablation.

Segreti L, Cori AD, Zucchelli G, Soldati E, Coluccia G, Viani S, Paperini L, Bongiorni MG.

J Atr Fibrillation. 2015 Apr 30;7(6):1172. doi: 10.4022/jafib.1172. eCollection 2015 Apr-May. Review.

14.

Electrical storm in dilated cardiomyopathy treated using epicardial radiofrequency ablation as a first line therapy.

Faustino M, Agricola T, Xyheri B, Di Girolamo E, Leonzio L, Pizzi C.

Indian Heart J. 2016 Sep;68 Suppl 2:S218-S222. doi: 10.1016/j.ihj.2016.01.010. Epub 2016 Jan 29.

15.

The Significance of Shocks in Implantable Cardioverter Defibrillator Recipients.

Li A, Kaura A, Sunderland N, Dhillon PS, Scott PA.

Arrhythm Electrophysiol Rev. 2016 Aug;5(2):110-6. doi: 10.15420/AER.2016.12.2.

16.

Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States.

Friedman DJ, Parzynski CS, Varosy PD, Prutkin JM, Patton KK, Mithani A, Russo AM, Curtis JP, Al-Khatib SM.

JAMA Cardiol. 2016 Nov 1;1(8):900-911. doi: 10.1001/jamacardio.2016.2782.

17.

Overview of implantable cardioverter defibrillator and cardiac resynchronisation therapy in heart failure management.

Chia PL, Foo D.

Singapore Med J. 2016 Jul;57(7):354-9. doi: 10.11622/smedj.2016117. Review.

18.

Anti-arrhythmic medications increase non-cardiac mortality - A meta-analysis of randomized control trials.

Pandya B, Spagnola J, Sheikh A, Karam B, Anugu VR, Khan A, Lafferty J, Kenigsberg D, Kowalski M.

J Arrhythm. 2016 Jun;32(3):204-11. doi: 10.1016/j.joa.2016.02.006. Epub 2016 Mar 11.

19.

ICD discrimination of SVT versus VT with 1:1 V-A conduction: A review of the literature.

Cardoso RN, Healy C, Viles-Gonzalez J, Coffey JO.

Indian Pacing Electrophysiol J. 2016 Feb 12;15(5):236-44. doi: 10.1016/j.ipej.2016.02.006. eCollection 2015 Sep-Oct. Review.

20.

Quality of Life in Patients with an Implantable Cardioverter Defibrillator: A Systematic Review.

Tomzik J, Koltermann KC, Zabel M, Willich SN, Reinhold T.

Front Cardiovasc Med. 2015 Nov 3;2:34. doi: 10.3389/fcvm.2015.00034. eCollection 2015. Review.

Supplemental Content

Support Center